The study found that 71% of previously untreated older patients experienced a complete or partial response to ibrutinib treatment. After 22 months of follow-up, the disease had not progressed in 96% of previously untreated patients. Ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL is promising.
Researchers found that ibrutinib effectively treats CLL with high response rates and durable remissions, particularly in elderly patients. The study also showed manageable toxicities, with only non-severe side effects observed.
Researchers at Fox Chase Cancer Center developed a novel 3D culture system to mimic the environment surrounding IBC cells. The model showed that the tumor microenvironment promotes proliferation, growth and invasion of IBC tumors.
Researchers examined current treatment standards for patients with clotting disorders, aiming to reduce toxicities and relapse rates. Maintaining hematocrit levels below 45% was associated with a lower risk of thrombosis compared to a more liberal approach.
Researchers found that a specific genetic marker, WT1 SNP rs16754, is correlated with improved outcomes and reduced treatment-related mortality in pediatric patients with AML. The study suggests personalized cancer treatment may improve survival and reduce toxicity by considering individual genetic makeup.